Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BCRX

Biocryst Pharmaceuticals Inc.

Sep 20 • 04:00PM ET

8.11

Dollar change -0.04
Percentage change -0.49	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF VB IWO VBK IBB SCHA PBE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.73	Insider Own	5.37%	Shs Outstand	205.77M	Perf Week	2.40%
Market Cap	1.68B	Forward P/E	-	EPS next Y	-0.17	Insider Trans	1.49%	Shs Float	195.77M	Perf Month	1.25%
Income	-145.93M	PEG	-	EPS next Q	-0.08	Inst Own	82.28%	Short Float	12.29%	Perf Quarter	26.32%
Sales	382.24M	P/S	4.39	EPS this Y	64.95%	Inst Trans	-1.63%	Short Ratio	9.35	Perf Half Y	47.72%
Book/sh	-2.30	P/B	-	EPS next Y	59.34%	ROA	-29.12%	Short Interest	24.06M	Perf Year	14.06%
Cash/sh	1.32	P/C	6.13	EPS next 5Y	44.80%	ROE	-	52W Range	4.03 - 8.88	Perf YTD	35.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.73%	ROI	-42.50%	52W High	-8.67%	Beta	1.88
Dividend TTM	-	Quick Ratio	2.78	Sales past 5Y	190.00%	Gross Margin	98.07%	52W Low	101.24%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	2.82	EPS Y/Y TTM	43.50%	Oper. Margin	-15.78%	RSI (14)	55.88	Volatility	3.11% 3.75%
Employees	536	Debt/Eq	-	Sales Y/Y TTM	24.65%	Profit Margin	-38.18%	Recom	1.18	Target Price	14.45
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	84.58%	Payout	-	Rel Volume	1.41	Prev Close	8.15
Sales Surprise	11.22%	EPS Surprise	65.32%	Sales Q/Q	32.54%	Earnings	Aug 05 BMO	Avg Volume	2.57M	Price	8.11
SMA20	0.29%	SMA50	4.76%	SMA200	31.17%	Trades		Volume	3,631,697	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight	$7
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy	$5 → $4
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4.50
Nov-16-18	Resumed	Piper Jaffray	Overweight	$15

Show Previous Ratings

Sep-17-24 07:00AM	BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks (GlobeNewswire)
Sep-12-24 01:25AM	BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals (GuruFocus.com)
Sep-06-24 02:00AM	BioCryst Presents New ORLADEYO (berotralstat) Data at 7th Bradykinin Symposium (GlobeNewswire)
Sep-05-24 07:00AM	BioCryst Appoints Dr. Donald Fong Chief Medical Officer (GlobeNewswire)
Sep-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Aug-22-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-05-24 01:00PM	BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript (Motley Fool) +6.98%
09:55AM	Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace)
Jul-29-24 10:00AM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
07:00AM	Loading…
Jul-22-24 07:00AM	BioCryst to Report Second Quarter 2024 Financial Results on August 5 (GlobeNewswire)
Jul-18-24 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High? (Zacks)
Jul-10-24 04:32AM	ORLADEYO gains approval in Peru for HAE prevention (Pharmaceutical Technology)
Jul-09-24 07:00AM	ORLADEYO (berotralstat) Approved in Peru (GlobeNewswire)
Jul-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-24 04:00AM	BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO (berotralstat) Treatment (GlobeNewswire)
May-15-24 01:13PM	BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases (MT Newswires) +18.66%
11:00AM	Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ... (GuruFocus.com)
11:00AM	Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
11:00AM	Insider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
11:00AM	Insider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
May-14-24 07:00AM	BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology (GlobeNewswire)
May-13-24 10:31AM	BioCryst Says Orladeyo Granted Approval in Mexico (MT Newswires) +5.83%
07:00AM	Loading…
07:00AM	ORLADEYO (berotralstat) Approved in Mexico (GlobeNewswire)
May-09-24 07:00AM	BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat) (GlobeNewswire)
May-07-24 11:51AM	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating (MT Newswires)
10:50AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
03:01AM	BioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
01:13AM	Q1 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-24 06:47PM	Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday (Motley Fool) +18.43%
04:59PM	BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance (Benzinga)
01:00PM	BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript (Motley Fool)
12:35PM	BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Tuesday, 5/6/2024 (Associated Press)
12:35PM	BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Monday, 5/6/2024 (Associated Press Finance)
11:53AM	BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:45AM	BioCryst Pharmaceuticals Shares Jump After Q1 Beat (MT Newswires)
08:32AM	BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts (GuruFocus.com)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	BioCryst: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-24 10:00AM	BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-24 07:00AM	BioCryst to Report First Quarter 2024 Financial Results on May 6 (GlobeNewswire)
Apr-17-24 05:14AM	Orladeyo gains approval in Brazil for HAE prevention (Pharmaceutical Business Review)
04:30AM	BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency (GlobeNewswire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
Apr-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-24 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-05-24 07:01AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:29AM	Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects (InvestorPlace)
Feb-28-24 10:47AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05AM	Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 04:45PM	BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript (Motley Fool)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	BioCryst Pharmaceuticals Inc (BCRX) Reports Growth in ORLADEYO Revenue and Projects ... (GuruFocus.com)
07:09AM	BioCryst: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones (GlobeNewswire)
Feb-23-24 07:00AM	BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment (GlobeNewswire)
Feb-21-24 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-19-24 07:54AM	BioCryst Launches ORLADEYO (berotralstat) in Italy (GlobeNewswire)
Feb-12-24 07:00AM	BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 (GlobeNewswire)
Feb-05-24 07:00AM	BioCryst to Present New ORLADEYO (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (GlobeNewswire)
Feb-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-24 09:25AM	BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last? (Zacks)
Jan-05-24 04:01PM	BioCryst Announces Preliminary Full Year 2023 ORLADEYO (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability (GlobeNewswire) -5.73% +25.62%
Jan-03-24 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.67%
07:00AM	BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 07:00AM	BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO (berotralstat) (GlobeNewswire)
Dec-05-23 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.11%
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks) +8.29%
Nov-29-23 07:00AM	BioCryst Announces Approval of ORLADEYO (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina (GlobeNewswire)
Nov-21-23 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire) -5.56% +5.29%
07:00AM	BioCryst Launches ORLADEYO (berotralstat) in Spain (GlobeNewswire)
Nov-10-23 07:00AM	BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO (berotralstat) (GlobeNewswire)
Nov-06-23 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-23 12:03PM	BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months (GlobeNewswire) +7.09%
12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire)
11:28AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
05:31AM	BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 08:53AM	BioCryst Pharmaceuticals Inc (BCRX) Reports Q3 2023 Earnings: ORLADEYO Revenue Up by 29.8% YoY (GuruFocus.com)
07:17AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	BioCryst to Present New ORLADEYO (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (GlobeNewswire)
Oct-26-23 07:00AM	BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013 (GlobeNewswire)
Oct-20-23 07:00AM	BioCryst to Host R&D Day on November 3 (GlobeNewswire)
Oct-19-23 07:00AM	BioCryst to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-04-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-23 07:00AM	INESSS Recommends Public Reimbursement for BioCrysts ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec (GlobeNewswire) +9.93%
Sep-05-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-23 08:30AM	3 Magnificent Growth Stocks to Buy on the Dip (Motley Fool)
Aug-23-23 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKee Amy E	Director	Jun 24 '24	Sale	6.32	8,600	54,352	27,831	Jun 25 04:39 PM
SANDERS MACHELLE	Director	Jun 17 '24	Sale	6.00	4,689	28,134	27,742	Jun 17 04:31 PM
HEGGIE THERESA	Director	Jun 14 '24	Sale	6.11	6,698	40,925	52,852	Jun 14 04:25 PM
LEVIN ALAN G	Director	May 30 '24	Buy	6.36	7,861	49,996	44,951	May 31 04:25 PM
ASELAGE STEVE	Director	May 24 '24	Buy	6.40	2,500	16,000	2,500	May 29 04:16 PM
Hutson Nancy J	Director	May 20 '24	Buy	6.38	5,000	31,900	86,818	May 22 07:24 AM
MILANO VINCENT	Director	May 20 '24	Buy	6.25	15,000	93,750	66,997	May 22 07:21 AM
Doyle Anthony	Chief Financial Officer	May 14 '24	Buy	5.57	36,300	202,191	266,744	May 15 07:19 AM
Thackray Helen M.	Chief R&D Officer	May 14 '24	Buy	5.86	30,000	175,800	272,139	May 15 07:17 AM
Galson Steven K	Director	May 13 '24	Buy	5.49	21,940	120,451	51,551	May 15 07:14 AM
Barnes Alane P	Chief Legal Officer	May 13 '24	Buy	5.53	5,000	27,650	300,762	May 15 07:11 AM
Stonehouse Jon P	President & CEO	May 13 '24	Buy	5.55	30,000	166,500	1,127,770	May 15 07:08 AM
Gayer Charles K	Chief Commercial Officer	May 13 '24	Buy	5.47	30,000	164,100	307,533	May 15 07:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCRX

Biocryst Pharmaceuticals Inc.

Upgrade your FINVIZ experience